Literature DB >> 24272458

Treatment of the sleep disorders associated with Parkinson's disease.

Lynn Marie Trotti1, Donald L Bliwise.   

Abstract

Sleep disorders are common in patients with Parkinson's disease (PD), and preliminary work has suggested viable treatment options for many of these disorders. For rapid eye movement sleep behavior disorder, melatonin and clonazepam are most commonly used, while rivastigmine might be a useful option in patients whose behaviors are refractory to the former. Optimal treatments for insomnia in PD have yet to be determined, but preliminary evidence suggests that cognitive-behavioral therapy, light therapy, eszopiclone, donepezil, and melatonin might be beneficial. Use of the wake-promoting agent modafinil results in significant improvement in subjective measures of excessive daytime sleepiness, but not of fatigue. Optimal treatment of restless legs syndrome and obstructive sleep apnea in PD are not yet established, although a trial of continuous positive airway pressure for sleep apnea was recently completed in PD patients. In those patients with early morning motor dysfunction and disrupted sleep, the rotigotine patch provides significant benefit.

Entities:  

Mesh:

Year:  2014        PMID: 24272458      PMCID: PMC3899483          DOI: 10.1007/s13311-013-0236-z

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  108 in total

1.  Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.

Authors:  Dan A Mendonça; Krishe Menezes; Mandar S Jog
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

2.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

3.  Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.

Authors:  A L Leeman; C J O'Neill; P W Nicholson; A A Deshmukh; M J Denham; J P Royston; R J Dobbs; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

4.  European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society.

Authors:  Diego Garcia-Borreguero; Luigi Ferini-Strambi; Ralf Kohnen; Shaun O'Keeffe; Claudia Trenkwalder; Birgit Högl; Heike Benes; Poul Jennum; Markku Partinen; Danyal Fer; Pasquale Montagna; Claudio L Bassetti; Alex Iranzo; Karel Sonka; Anne-Marie Williams
Journal:  Eur J Neurol       Date:  2012-09-03       Impact factor: 6.089

5.  Dopaminergic role in stimulant-induced wakefulness.

Authors:  J P Wisor; S Nishino; I Sora; G H Uhl; E Mignot; D M Edgar
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

6.  Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

Authors:  R Pahwa; M A Stacy; S A Factor; K E Lyons; F Stocchi; B P Hersh; L W Elmer; D D Truong; N L Earl
Journal:  Neurology       Date:  2007-04-03       Impact factor: 9.910

7.  Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Cathy Wood-Siverio; Jorge J Juncos; Stewart A Factor; Alan Freeman; David B Rye
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

8.  Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

Authors:  William G Ondo; Thomas Perkins; Todd Swick; Keith L Hull; J Ernesto Jimenez; Tippy S Garris; Daniel Pardi
Journal:  Arch Neurol       Date:  2008-10

9.  Treatment outcomes in REM sleep behavior disorder.

Authors:  Stuart J McCarter; Christopher L Boswell; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Bradley F Boeve; Michael H Silber; Eric J Olson; Maja Tippmann-Peikert
Journal:  Sleep Med       Date:  2013-01-23       Impact factor: 3.492

10.  Predictors and course of health-related quality of life in Parkinson's disease.

Authors:  Elin Bjelland Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Karen Herlofson; Guido Alves
Journal:  Mov Disord       Date:  2008-07-30       Impact factor: 10.338

View more
  25 in total

Review 1.  Idiopathic Hypersomnia.

Authors:  Lynn Marie Trotti
Journal:  Sleep Med Clin       Date:  2017-06-16

2.  Editorial: Neurotherapeutics of movement disorders.

Authors:  Stewart A Factor; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Parkinson's disease and sleep/wake disturbances.

Authors:  Keisuke Suzuki; Masayuki Miyamoto; Tomoyuki Miyamoto; Koichi Hirata
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

4.  Comparing Gabapentin with Clonazepam for Residual Sleeping Problems following Antidepressant Therapy in Patients with Major Depressive Disorder: A Randomized Clinical Trial.

Authors:  Arash Mowla; Laaya Ahmadzadeh; Leila Razeghian Jahromi; Seyed Ali Dastgheib
Journal:  Clin Drug Investig       Date:  2015-08       Impact factor: 2.859

Review 5.  Management of sleep disorders in Parkinson's disease and multiple system atrophy.

Authors:  Aleksandar Videnovic
Journal:  Mov Disord       Date:  2017-01-24       Impact factor: 10.338

6.  An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.

Authors:  Yan Wang; Yue-Chang Yang; Dan-Mei Lan; Hui -Juan Wu; Zhong-Xin Zhao
Journal:  Sleep Breath       Date:  2016-10-11       Impact factor: 2.816

Review 7.  [Parkinson's disease in the elderly].

Authors:  Rüdiger Lange; Frank Erbguth
Journal:  Z Gerontol Geriatr       Date:  2017-07-19       Impact factor: 1.281

8.  Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.

Authors:  Shanna L Burke; Tianyan Hu; Christine E Spadola; Tan Li; Mitra Naseh; Aaron Burgess; Tamara Cadet
Journal:  Sleep Med       Date:  2018-09-20       Impact factor: 3.492

9.  Sleep dysfunction and its management in Parkinson's disease.

Authors:  Scott J Kutscher; Siavash Farshidpanah; Daniel O Claassen
Journal:  Curr Treat Options Neurol       Date:  2014-08       Impact factor: 3.598

10.  Outcomes of Cognitive-Behavioral Treatment for Insomnia on Insomnia, Depression, and Fatigue for Individuals with Multiple Sclerosis: A Case Series.

Authors:  Megan Clancy; Michelle Drerup; Amy Burleson Sullivan
Journal:  Int J MS Care       Date:  2015 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.